Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 718

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 718
---
 of business. For the year ended June 30, 2024, the Company reported a loss of $ 8,320and a negative cash flow from operations of $ 7,176. The Company had an accumulated deficit of $ 159,876and had cash and cash equivalents of $ 4,909as of June 30, 2024. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. On August 2, 2022, the Company entered into a stock purchase agreement under which the Company has issued 662shares of common stock for $ 2,008in net F-8

proceeds as of June 30, 2024. In addition, on June 28, 2023, the Company announced that it had been awarded approximately $ 2,000in grant funding to be received over a two-yearperiod for its REM-001project.During the year ended June 30, 2024, the Company issued an additional 53,151shares of common stock for net proceeds of $ 10,471from its at-the-market(“ATM”) facility, issued an additional 400shares of common stock for net proceeds of $ 105from its Lincoln Park Purchase Agreement (Note 8), and announced that it is suspending the development of VAL-083.Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one yearfrom the date of filing of these condensed consolidated interim financial statements. On April 2, 2024, the Company entered into a merger agreement with TuHURA Biosciences, Inc. Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or entering into strategic partnership arrangements. However, the Company’s ability to raise additional capital could be affected by various risks and uncertainties including, but not limited to, global unrest. The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company